GH Research Past Earnings Performance
Past criteria checks 0/6
GH Research's earnings have been declining at an average annual rate of -72.7%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually.
Key information
-72.7%
Earnings growth rate
-67.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -16.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Mar 01
GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Nov 17GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Jul 30We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely
Mar 13Companies Like GH Research (NASDAQ:GHRS) Are In A Position To Invest In Growth
Nov 28GH Research GAAP EPS of $0.006
Aug 23We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
Aug 15GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Apr 29We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate
Jan 13GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Sep 30GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry
Aug 15Revenue & Expenses BreakdownBeta
How GH Research makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -36 | 11 | 30 |
| 30 Sep 23 | 0 | -41 | 11 | 28 |
| 30 Jun 23 | 0 | -36 | 10 | 26 |
| 31 Mar 23 | 0 | -28 | 10 | 23 |
| 31 Dec 22 | 0 | -22 | 10 | 20 |
| 30 Sep 22 | 0 | -10 | 11 | 17 |
| 30 Jun 22 | 0 | -11 | 11 | 15 |
| 31 Mar 22 | 0 | -14 | 9 | 13 |
| 31 Dec 21 | 0 | -9 | 7 | 9 |
| 30 Sep 21 | 0 | -5 | 3 | 5 |
| 30 Jun 21 | 0 | -4 | 1 | 3 |
| 31 Mar 21 | 0 | -2 | 1 | 1 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: GHRS is currently unprofitable.
Growing Profit Margin: GHRS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GHRS is unprofitable, and losses have increased over the past 5 years at a rate of 72.7% per year.
Accelerating Growth: Unable to compare GHRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GHRS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: GHRS has a negative Return on Equity (-16.25%), as it is currently unprofitable.